A Phase 3 interventional study of IDP-126 Gel and IDP-126 Vehicle Gel in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 22nd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2020, is one of 13 in phase 3, and was the 32nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
By country, each count listing its studies:
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 247 across the 35 interventional studies, 200 across the 1 observational. Of the 31 that completed or were terminated, 19 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IDP-126 Gel
Drug: IDP-126 Vehicle Gel
IDP-126 Gel applied topically to the face once daily for 12 weeks.
IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts
Time frame: 12 weeks
Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
Time frame: 12 weeks
Percentage of Participants With Success on the Evaluator's Global Severity Score
Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: 12 weeks
Inflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
Time frame: Baseline to Week 4, 8, 12
Noninflammatory Lesion Count Percentage Changes at Week 4, 8, and 12
Time frame: Baseline to Week 4, 8, 12
Percentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 12
The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: 12 weeks
| Milestone | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Started | 120 | 60 |
| Completed | 107 | 56 |
| Not completed | 13 | 4 |
| lesion counts | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts | -30.1 ± 9.64 | -20.8 ± 9.90 |
| lesion counts | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts | -35.2 ± 14.48 | -22.0 ± 14.27 |
Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| percentage of participants | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Percentage of Participants With Success on the Evaluator's Global Severity Score | 50.5 | 20.5 |
| percentage change | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Week 4 | -57.40 ± 29.412 | -41.62 ± 26.854 |
| Week 8 | -70.38 ± 27.018 | -47.62 ± 26.343 |
| Week 12 | -80.13 ± 25.274 | -56.18 ± 25.149 |
| percentage change | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Week 4 | -45.07 ± 32.748 | -33.05 ± 29.290 |
| Week 8 | -60.62 ± 28.041 | -45.54 ± 26.604 |
| Week 12 | -73.26 ± 27.640 | -48.99 ± 27.345 |
The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| percentage of participants | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Percentage of Participants With at Least a Two Grade Reduction on the Evaluator's Global Severity Score at Week 12 | 55.2 | 23.1 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDP-126 Gel | 0/120 (0%) | 0/120 (0%) | 18/120 (15%) |
| IDP-126 Vehicle Gel | 0/60 (0%) | 0/60 (0%) | 1/60 (1.7%) |
| Event | IDP-126 Gel | IDP-126 Vehicle Gel |
|---|---|---|
| Application site painGeneral disorders | 18/120 | 1/60 |
| Age, Continuous(years) | IDP-126 Gel | IDP-126 Vehicle Gel | Total |
|---|---|---|---|
| Median | 17.0 (10 to 48) | 19.5 (11 to 43) | 18.0 (10 to 48) |
| Sex: Female, Male(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Total |
|---|---|---|---|
| Female | 69 | 37 | 106 |
| Male | 51 | 23 | 74 |
| Race (NIH/OMB)(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 5 | 17 |
| White | 94 | 53 | 147 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 1 | 7 |
| Baseline Evaluator's Global Severity Score(Participants) | IDP-126 Gel | IDP-126 Vehicle Gel | Total |
|---|---|---|---|
| Moderate | 109 | 57 | 166 |
| Severe | 11 | 3 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2020 to primary completion in Mar 2021, 13 months.
Results were first posted in Feb 2024, 2 years 10 months after primary completion. A results delay was requested in Mar 2022.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IDP-126
Bausch Health Americas, Inc. →